BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer's Disease
Alzheimer’s disease (AD) is a growing global health concern with a massive impact on affected individuals and society. Despite the considerable advances achieved in the understanding of AD pathogenesis, researchers have not been successful in fully identifying the mechanisms involved in disease prog...
Saved in:
Main Authors: | Miguel A. Maia (Author), Emília Sousa (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2019-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Expression analysis of beta-secretase 1 (BACE1) enzyme in peripheral blood of patients with Alzheimer\'s disease
by: Alireza Vakilian, et al.
Published: (2019) -
Structural Analysis of the Simultaneous Activation and Inhibition of γ-Secretase Activity in the Development of Drugs for Alzheimer's Disease
by: Željko M. Svedružić, et al.
Published: (2021) -
Effects of the γ-secretase inhibitor semagacestat on hippocampal neuronal network oscillation
by: Mihaly eHajos, et al.
Published: (2013) -
Molecular Multi-Target Approach for Human Acetylcholinesterase, Butyrylcholinesterase and <i>β</i>-Secretase 1: Next Generation for Alzheimer's Disease Treatment
by: Géssica Oliveira Mendes, et al.
Published: (2023) -
miRNA-31 Improves Cognition and Abolishes Amyloid-β Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimer's Disease
by: Ana Teresa Barros-Viegas, et al.
Published: (2020)